Immunotherapy as part of combinations for the treatment of cancer (Q35177544)

6 August 2017

1 reference

title

Immunotherapy as part of combinations for the treatment of cancer (English)

1 reference

6 August 2017

1 reference

Malcolm S Mitchell

1 reference

6 August 2017

publication date

1 August 2003

1 reference

International Immunopharmacology

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

1051-1059

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

ICOS co-stimulatory receptor is essential for T-cell activation and function

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

The Emerging Role of CTLA-4 as an Immune Attenuator

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Phase II Trial of Interleukin-2 and Interferon-ce in Patients with Renal Cell Carcinoma: Clinical Results and Immunologic Correlates of Response

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900019-5

7 January 2021

10.1016/S1567-5769(03)00019-5

Identifiers

DOI

1 reference

release_iletsodrsvazvkhzkvglfq37lq

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iletsodrsvazvkhzkvglfq37lq

24 November 2022

mapped directly with Wikidata item

1 reference